期刊文献+

羽苔素E体外抗真菌活性及逆转氟康唑耐药的初步研究 被引量:7

Primary Study on Antifungal Activities and Reversal of Fluconazole Resistance of Plagiochin E
下载PDF
导出
摘要 目的评价白色念珠菌对羽苔素E的体外敏感性,并观察羽苔素E和氟康唑合用对白念敏感株和耐药株的联合抗真菌作用。方法采用微量稀释法,测定15株白念敏感株和4株白念耐药株对羽苔素E的敏感性,以最低抑菌浓度(MIC)表示。同时观察羽苔素E与氟康唑合用对白念敏感株和耐药株的联合抗真菌作用。结果羽苔素E对敏感株的MIC值为16 mg.L-1,对耐药株的MIC值与敏感株基本一致。羽苔素E与氟康唑合用,对敏感株和耐药株分别表现出相加和协同的抗真菌活性,并明显减少氟康唑的用量。结论羽苔素E具有中等的抗真菌活性,与氟康唑合用对耐药菌株表现出协同的抗真菌作用,提示羽苔素E有较好的抗真菌作用并有逆转氟康唑耐药的潜力。 OBJECTIVE To investigate the antifungal activity of plagiochin E against the strains of Candida albicans in vitro, and the interactions of fluconazole with plagiochin E against the sensitive and resistant strains. METHODS A broth micro-dilution method was used to determine the MICs of plagiochin E for the fifteen sensitive and four resistant strains. The combination effect of plagiochin E and fluconazole was also assessed. RESULTS The MIC of plagiochin E was 16 mg · L^-1 against the fifteen sensitive strains. Plagiochin E had the same MIC against resistant strains. After the administration of plagiochin E and fluconazole at the same time, MICs of two drugs were lower against both resistant strains and sensitive ones. Additive effect on sensitive strains and synergic effect on resistant strains were observed respectively. CONCLUSION Plagiochin E has a moderate but significant antifungal action on the sensitive and resistant strains of C. albicans, and shows additive or synergy effect after the administration of fluconazole. Plagiochin E can be useful for antifungal therapy and has a potential action on reversing the resistance of C. albicans against flueonazole.
机构地区 山东大学药学院
出处 《中国药学杂志》 CAS CSCD 北大核心 2007年第5期349-352,共4页 Chinese Pharmaceutical Journal
基金 国家自然科学基金资助课题(30271537)
关键词 羽苔素E 氟康唑 白色念珠菌 逆转耐药 plagiochin E fluconazole Candida albicans reversing resistance
  • 相关文献

参考文献9

  • 1VANDEN B H,ENGELEN M,ROCHETTE F.Antifungal agents of use in animal health-chemical,biochemical and pharmacological aspects[J].Vet Pharmacol Ther,2003,26(1):5-29.
  • 2National Committee for Clinical Laboratory Standards.Reference method for broth dilution antifugal susceptibility testing of yeasts;approved standard[S].NCCLS document M27-A,Wayne,1997.
  • 3SANDERS C C,SANDERS W E J R,MOLAND E S.Decimal assay for additivity of drugs permits delineation of synergy and antagonism[J].Antimicrob Agents Chemother,1993,37 (2):260-264.
  • 4韩旭东,张永信,章强强.白色念珠菌对氟康唑耐药性的诱导和回复研究[J].中国抗生素杂志,2004,29(6):374-377. 被引量:10
  • 5PRASAD R,KAPOOR K.Multidrug resistance in yeast Candida[J].Int Rev Cytol,2004,242(1):215-248.
  • 6MARR K A,LYONS C N,H A K,et al.Inducible azole resistance associated with a heterogeneous phenotype in Candida albicans[J].Antimicrob Agents Chemother,2001,45 (1):52-59.
  • 7MARR K A,LYONS C N,RUSTAD T R,et al.Rapid,transient fluconazole resistance in Candida albicans is associated with increased mRNA levers of CDR[J].Antimicrob Agents Chemother,1998,42(10):2584-2589.
  • 8GRAYBILL J R,NAJVAR L K,HOLMBERG J D,et al.Fluconazole treatment of Candida albicans infection in mice:does in vivo susceptibility predict in vivo response[J].Antimicrob Agents Chemother,1995,39(10):2197-2200.
  • 9MIOT,YABET,SUDOH M,et al.Role of three chitin synthase genes in the growth of Candida albicans[J].J Bacteriol,1996,178(8):2416-2419.

二级参考文献11

  • 1Law D, Moore C B, Wardle H M, et al. High prevalence of antifungal resistance in Candida spp from patients with AIDS [J]. J Antimicrob Chemother,1994,34(5):659
  • 2Chavanet P, Lopez J, Grappin M, et al. Cross-sectional study of the susceptibility of Candida isolates to antifungal drugs and in vitro-in vivo correlation in HIV-infected patients [J]. AIDS,1994,8(7):945
  • 3National committee for clinical laboratory standards. Referenced method for broth dilution antifungal susceptibility testing of yeasts [M]. Approved standard M27-A. Pennsylvania: NCCLs, 1997,17(9):1
  • 4Pfaller M A, Jones R N, Messer S A, et al. National surveillance of nosocomial blood stream infection due to Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program [J]. Diagn Microbiol Infect Dis,1998,31(1):327
  • 5Viudes A, Peman J, Canton E, et al. Candidemia at a tertiary-care hospital: epidemiology, treatment, clinical outcome and risk factors for death [J]. Eur J Clin Microbiol Infect Dis,2002,21(11):767
  • 6McGuire W, Clerihew L, Austin N. Prophylactic intravenous antifungal agents to prevent mortality and morbidity in very low birth weight infants [J]. Cochrane Database Syst Rev,2003,(1):CD00385
  • 7Bow E J, Laverdiere M, Lussier N, et al. Antifungal prophylaxis for severely neutropenic chemotherapy recipients:a meta analysis of randomized-controlled clinical trials [J]. Cancer,2002,94(12):3230
  • 8Millon L, Manteaux A, Reboux G, et al. Fluconazoleresistant recurrent oral candidiasis in human immunodeficiency virus-positive patients: persistence of Candida albicans strains with the same genotype [J]. J Clin Microbiol,1994,32(4):1115
  • 9Marr K A, Lyons C N, Ha K, et al. Inducible azole resistance associated with a heterogeneous phenotype in Candida albicans [J]. Antimicrob Agents Chemother, 2001,45(1):52
  • 10Marr K A, Lyons C N, Rustad T R, et al. Rapid, transient fluconazole resistance in Candida albicans is associated with increased mRNA levels of CDR [J]. Antimicrob Agents Chemother , 1998,42(10):2584

共引文献9

同被引文献51

引证文献7

二级引证文献87

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部